NCT06646419Completed
Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle
Boosting Regional Integration for COPD Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle: A Multicentre , Prospective, Cluster Randomization, Inteventional Clinical Study
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
This is a cluster randomized interventional study. Intervention is implemented at a hospital level and will change overall daily practice. 36 county level hospitals are r an domized to the intervention group or control group at the ratio of 2:1 . Total subjects is 1368 and a size of 38 per hospital .
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1368 (actual)
- First submitted
- 29 Aug 2024
- Start date
- 13 Nov 2024
- Primary completion date
- 21 Sept 2026
- Lead sponsor
- AstraZeneca
- Diseases
- COPD
- NCT number
- NCT06646419
What you commit to
- Study type: Observational
- Participants enrolled: 1368
- From 13 Nov 2024 to the primary completion date, 21 Sept 2026
- 37 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Continuous triple inhalation therapy for ≥6 months at baseline (include single inhaler and multiple inhalers)
Other illness
- Stable COPD (symptom such as cough, sputum and shortness of breath are mild or stable, clinical condition has basically returned to pre-exacerbation)
- Comorbidities require/contraindicate long-term use of glucocorticoid treatment: asthma, interstitial lung disease, sarcoidosis, cystic fibrosis, active tuberculosis recurrent aspiration pneumonia ect.
- Serious comorbidities threaten to life expected survival time no more than 1 year: severe heart disease, severe chronic liver, severe kidney disease, cerebrovascular disease with long-term bed rest and malignant tumours ect.
Other
- Not living in the healthcare area
- Patients currently participating in any other interventional studies
Who the study is looking for
- Diagnosed COPD (post- bronchodilator FEV1/FVC \< 0.7)
- 40\~80 years
- CAT≥10
- At least two moderate or at least one severe exacerbation history in past 1 year
- Able to sign informed consent
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (37)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.